http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108606981-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-46 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate | 2018-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108606981-B |
| titleOfInvention | Application of MSCs (mesenchymal stem cells) directed chemotactic property to carry EPO (erythropoietin) for treating pulmonary fibrosis |
| abstract | The invention relates to a method for treating pulmonary fibrosis by using MSCs (mesenchymal stem cells) with directional chemotactic property to carry EPO (erythropoietin). MSCs are used as carriers, EPO gene is introduced by adopting a genetic engineering means, EPO is secreted in lung organs and forms a microenvironment locally, MVs carrying anti-inflammatory and anti-fibrosis molecules are promoted to be secreted, and the EPO enters lung cells through the cytothesis to achieve fibrosis. Therefore, MSCs carrying and expressing EPO can directly target pulmonary fibrosis organs, improve the combination efficiency and achieve the effect of getting twice with half the effort. Meanwhile, the biological half-life period can be effectively prolonged, MSCs are promoted to secrete anti-inflammatory and anti-fibrosis molecules, and the treatment effect is improved. |
| priorityDate | 2018-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 82.